Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 3Tumor-Agnostic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Rosuvastatin Calcium × Tumor-Agnostic × Clear all
NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

pharmaand GmbH

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT02106845 2019-06-07

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Bayer

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡